{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-084615","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.524359+00:00","generated_at":"2026-05-31T13:54:51.788445+00:00","sec_items":["1.01","2.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Passage Bio out-licenses three pediatric gene therapy programs to GEMMABio, extends cash runway to Q2 2026","bullets":["Out-licensed PBGM01, PBKR03, PBML04 to GEMMABio; initial $10M + up to $124M milestones + royalties.","Cash of ~$91.8M at June 30, 2024; operating runway extended to end of Q2 2026.","CMO Mark Forman resigned effective Aug 2, 2024; no disagreement with company.","Appointed Susan Browne as CSO and Stuart Henderson as CBO effective Aug 1, 2024.","Entered new collaboration with GEMMABio to advance CNS programs including Huntington's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-084615","json":"https://secwatch.observer/filing/0001104659-24-084615.json","markdown":"https://secwatch.observer/filing/0001104659-24-084615.md","text":"https://secwatch.observer/filing/0001104659-24-084615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/0001104659-24-084615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/tm2420570d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:54:51.788445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd872bc8db","claim":"Mark Forman resigned as Chief Medical Officer at Passage BIO, Inc..","evidence_excerpt":"On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000110465924084615/0001104659-24-084615-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}